Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients

Endocrine Journal

Volumn 57, Issue 9, 2010, Pages 777-786

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a   Ferrari, Ilaria ^a   D'Angelo, Angela ^a   Fogari, Elena ^a   Palumbo, Ilaria ^a   Randazzo, Sabrina ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

HOMA IR; Insulin resistance; L carnitine; Orlistat; Type 2 diabetes

Indexed keywords

ACARBOSE; C REACTIVE PROTEIN; CARNITINE; CHOLESTEROL; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; RESISTIN; RETINOL BINDING PROTEIN 4; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VILDAGLIPTIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANTI-OBESITY AGENTS; BODY WEIGHT; CARNITINE; DIABETES MELLITUS, TYPE 2; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; LACTONES; MALE; MIDDLE AGED; OBESITY;

EID: 77957733692     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-049     Document Type: Article

References (41)

1. Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880.
2. Leung WY, Thomas GN, Chan JC, Tomlinson B (2003) Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 25 (1): 58-80.
3. Wong NN, Cheng-Lai A (2000) Orlistat Heart Dis 2: 174-181.
4. Zhi J, Moore R, Kanitra L, Mulligan TE (2002) Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 42: 1011-1019.
5. MacWalter RS, Fraser HW, Armstrong KM (2003) Orlistat enhances warfarin effect. Ann Pharmacother 37: 510-512.
6. Rebouche CJ, Bosch EP, Chenard CA, Schabold KJ, Nelson SE (1989) Utilization of dietary precursors for carnitine synthesis in human adults. J Nutr 119: 1907-1913.
7. Newsholme EA, Leech AR (1983) Biochemistry for Medical Sciences. John Wiley and Sons, Chichester: 318-321.
8. Uziel G, Garavaglia B, Di Donato S (1988) Carnitine stimulation of pyruvate dehydrogenase complex (PDHC) in isolated human skeletal muscle mitochondria. Muscle Nerve 11: 720-724.
9. Amat di San Filippo C, Taylor MR, Mestroni L, Botto LD, Longo N (2008) Cardiomyopathy carnitine deficiency. Mol Genet Metab 94: 162-166.
10. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD) (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28 (1): 88-136.
11. World Health Organization (1997) Obesity: preventing and managing the global epidemic. Report of WHO consultation on obesity. WHO, Geneva.
12. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J (2006) Summary of American Heart Association Diet and Lifestyle Recommendations Revision. Arterioscler Thromb Vasc Biol 26: 2186-2191.
13. Bunn HF, Gabbay KH, Gallop PM (1978) The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 200: 21-27.
14. European Diabetes Policy Group (1999) A desktop guide to type 2 diabetes mellitus. Diabet Med 16: 716-730.
15. Heding LG (1972) Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8: 260-266.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
17. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495.
18. Klose S, Borner K (1978) Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 15: 121-130.
19. Wahlefeld AW (1974) Triglycerides determination after enzymatic hydrolysis. In: Bergmeyer HU (ed) Methods of Enzymatic Analysis. 2nd English ed. Academic Press, New York: 18-31.
20. Havel RJ, Edr HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353.
21. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
22. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inumai T (2007) Retinol binding protein-4 and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 92: 2712-2719.
23. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS (2003) Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 88: 1730-1736.
24. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W (2007) Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 92: 4783-4791.
25. Rifai N, Tracy RP, Ridker PM (1999). Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay. Clin Chem 45 (12): 2136-2141.
26. nd ed, McGraw-Hill, New York.
27. Derosa G, Mugellini A, Ciccarelli L, Rinaldi, Foga ri R (2002) Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial. Curr Ther Res Clin Exp 63: 621-633.
28. Derosa G, Mugellini A, Ciccarelli L, Fogari R (2003) Randomized double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 25: 1107-1122.
29. Derosa G, Cicero AFG, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R (2005) Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 7: 47-55.
30. Derosa G, Cicero AFG, Gaddi A, Mugellini A, Ciccarelli L, Fogari R (2003) The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 25 (5): 1429-1439.
31. Sirtori CR, Calabresi L, Ferrara S, Pazzucconi F, Bondioli A, Baldassarre D, Birreci A, Koverech A (2000) L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis 10: 247-251.
32. Li YB, Zhu DL, Tian HM, Shi LX, Luo ZJ, Yan L, Zeng LY, Zhou ZG, Yang LY, Liu J, Li M, Weng JP (2006) Characteristics of dysfunction of islet beta-cell in newly diagnosed type 2 diabetic patients. Zhonghua Yi Xue Za Zhi 86 (36): 2537-2541.
33. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS (2006) Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 29: 2457-2461.
34. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature (London) 409: 307-312
35. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I and Olefsky JM (2004) Adenovirus-mediated chronic 'hyper-resistinemia' leads to in vivo insulin resistance in normal rats. J Clin Invest 114: 224-231.
36. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA (2004) Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53: 1937-1941.
37. Reilly MP, Lehrke M, Wolfe M, Rohatgi A, Lazar MA, Rader DJ (2005). Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111: 932-939.
38. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430.
39. Hug C and Lodish HF (2005) Visfatin: a new adipokine. Science 307: 366-367.
40. Zwacka TP, Hornbach V, Torzewski J (2001) C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 103: 1194-1197.
41. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R (2004) Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab 17 (4): 222-229.